BridgeBio Pharma Inc.
BridgeBio Reports Strong Financial Results and Commercial Progress for Attruby
Summary
BridgeBio Pharma, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, showing a significant increase in revenue primarily due to the first commercial sales of Attruby and service revenue from Bayer and Kyowa Kirin agreements. Despite the increased revenue, the company reported a net loss for both the quarter and the full year. The company ended the year with $681 million in cash, cash equivalents, and short-term restricted cash. Attruby has seen strong uptake with 1,028 unique patient prescriptions written since FDA approval. BridgeBio also provided updates on its clinical trials, with several studies fully enrolled and expected to report topline results in the second half of 2025.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement